Foreign drug makers fear disgraced corporate image over rebate scandal

With the Fair Trade Commission's second announcement of rebate scandal involving several foreign-invested pharmaceutical firms, there are growing concerns that the commission's disclosure will tarnish the reliability and morality of these foreign players throughout the world.

Enforcing a principle-based approach is more difficult when the company is part of an industry where certain practice...